Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Low-Dose Aspirin for the Prevention of Venous Thromboembolism in Patients Receiving Chemotherapy for Testicular Cancer or Advanced Germ Cell Tumors, ASPIRE GCT Trial

Trial Status: active

This phase II trial studies how well low-dose aspirin (ASA) works in preventing blood clots in the veins (venous thromboembolism [VTE]) in patients receiving chemotherapy for testicular cancer or germ cell tumors (GCTs) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Patients who are being treated with the type of chemotherapy used for testicular cancer and GCTs are at a higher risk of developing blood clots. Low-dose ASA contains a lower dose of ASA than a standard adult tablet, usually between 81 and 100mg. ASA in varying doses has been shown to reduce the blood clot rate in bone trauma, hip replacement, and multiple myeloma (a blood cancer) treatment. Low-dose ASA may be effective in preventing VTE in patients receiving chemotherapy for testicular cancer or advanced GCTs.